Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.

Sci Rep · 2021 · PMC8155022 · PMID 34040108

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

At the RNA level, JNJ-61803534 significantly inhibited IMQ-induced expression of IL-17A, IL-17F, and IL-22 genes at 100 mg/kg and also showed a trend towards inhibition of IL-17A and IL-17F expression at 30 mg/kg and IL-23R at 30 and 100 mg/kg, respectively (Fig. 5 b).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.